Carcinoma Clinical Trials

A listing of Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1605 clinical trials
Featured trial
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.

  • 1199 views
  • 21 Apr, 2022
  • 84 locations
Featured trial
Study of INCA 0186 in Subjects With Advanced Solid Tumors

preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in participants with specific advanced solid tumors; squamous cell carcinoma of the head and neck

  • 0 views
  • 17 May, 2022
  • 6 locations
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.  

urothelial carcinoma
bladder cancer
bladder carcinoma
metastatic urothelial carcinoma
  • 243 views
  • 10 May, 2022
  • 64 locations
Featured trial
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy

The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after

chemotherapy regimen
measurable disease
platinum-based chemotherapy
  • 92 views
  • 10 May, 2022
  • 24 locations
Featured trial
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

solid tumors
cancer
  • 55 views
  • 10 May, 2022
  • 9 locations
Featured trial
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).  

metastatic merkel cell carcinoma
merkel cell carcinoma
measurable disease
metastatic cancer
cancer
  • 101 views
  • 10 May, 2022
  • 7 locations
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

advanced cancer
cancer
  • 226 views
  • 10 May, 2022
  • 4 locations
Featured trial
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose …

urothelial carcinoma
ovarian cancer
metastatic cervical cancer
carcinoma
  • 380 views
  • 10 May, 2022
  • 4 locations
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free

mk-3475
pembrolizumab
cancer
adjuvant therapy
  • 117 views
  • 11 May, 2022
  • 130 locations
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

adenosine A2A receptor antagonist), in patients with advanced clear cell renal cell carcinoma and other malignancies with HIF stabilizing mutations.

everolimus
mtor inhibitor
rad001
clear cell renal cell carcinoma
vegf
  • 16 views
  • 02 May, 2022
  • 8 locations